ORPHA:521426
PLAA-associated neurodevelopmental disorder
Also known as: PLAAND
Publications
1,526
Trials
0
Interventional, condition-specific
Researchers
646
Distinct authors in sample
Gene link
PLAA
Strong
Readiness
4/6
Stages with a signal
Clinical definition (Orphanet)
A rare genetic neurological disorder characterized by onset of leukoencephalopathy, microcephaly, severe global , and spasticity resulting in quadriparesis and posture deformation. Additional features include an abnormally exaggerated startle reflex, , dystonia, and hypomimia or amimia, as well as chest deformities and contractures of large and hyperextensibility of small joints, among others. Thin corpus callosum is a prominent feature in brain imaging, in addition to white matter abnormalities consistent with leukoencephalopathy.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0060502
- OMIM:617527
- UMLS:C4479631
Additional Mondo synonyms (1)
neurodevelopmental disorder with progressive microcephaly, spasticity, and brain anomalies
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
4/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedPresent
Strong — PLAA
- LiteraturePresent
1,526 matched papers (658 in last 10 years) Source
- Phenotype characterisedPresent
115 HPO annotations (e.g. Micrognathia; Posteriorly rotated ears; Optic atrophy) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPartial
None under the specific name; 40 for broader category neurodevelopmental disorder
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (PLAA).
GenCC classification: Strong.
Phenotypes (Monarch / HPO)
115
Associated phenotypes · MONDO:0060502
- Micrognathia
- Posteriorly rotated ears
- Optic atrophy
- Postaxial hand polydactyly
- Hyperextensibility of the finger joints
Showing 5 of 115 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
1,526
1,526 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
1,526 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
658 in the last 10 years · low confidence
Phrase hits: 98 · MeSH hits: 0
Who's working on it?
646
Distinct author names in 98 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Elsea SH6 papers · 2023
Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
Papers in Europe PMC - 02Chen L3 papers · 2020
Department of Cellular and Genetic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Papers in Europe PMC - 03Jensik PJ3 papers · 2023
Department of Physiology, Southern Illinois University School of Medicine, Carbondale, Illinois.
Papers in Europe PMC - 04LINTAS CARLA3 papers · 2010Papers in Europe PMC
- 05Liu C3 papers · 2025
Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, China.
Papers in Europe PMC - 06Mullegama SV3 papers · 2021
Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Papers in Europe PMC - 07Pierson TM3 papers · 2024
Department of Pediatrics, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Tyler.Pierson@cshs.org.
Papers in Europe PMC - 08SACCO ROBERTO3 papers · 2010Papers in Europe PMC
- 09Bain JM2 papers · 2025
Department of Neurology, Division of Child Neurology, Columbia University Irving Medical Center, New York, USA.
Papers in Europe PMC - 10Balasubramanian M2 papers · 2025
Senior Clinical Lecturer, Department of Oncology & Metabolism, University of Sheffield, Consultant Clinical Geneticist, Sheffield Clinical Genetics Service, Lead Consultant, OI-Genetics Service, Highly Specialised Severe, Complex & Atypical OI Service, Sheffield Children's NHS Foundation Trust
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 40 trials are registered for neurodevelopmental disorder, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
low confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
40 interventional trials matched neurodevelopmental disorder, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: neurodevelopmental disorder
40
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07667023·ENROLLING BY INVITATION·Virtual Reality Headset as an Alternative Tool for Reducing Dental Anxiety
Conditions: Neurodevelopmental Disorder (Diagnosis)·Matched via name phrase
- NCT07614126·RECRUITING·Study of L-dopa Treatment in Patients With a Neurodevelopmental Disorder (CTNNB1 Gene)
Conditions: CTNNB1 · L-DOPA·Matched via name phrase
- NCT07303049·NOT YET RECRUITING·Cognitive Benefit of Intensive Rehabilitation Using Rhythmic Music Training in Children With Complex Neurodevelopmental Disorder
Conditions: Complex Neurodevelopmental Disorder·Matched via name phrase
- NCT06027645·RECRUITING·Early Intervention Based on Neonatal Crawling in Very Premature Infants at Risk For Neurodevelopmental Disorder
Conditions: Prematurity · Extreme Prematurity · Infant Development · Brain Damage·Matched via name phrase
- NCT06851377·RECRUITING·Expanding NGS Data with Optical Genome Mapping (OGM)
Conditions: Neurodevelopmental Disorder (Diagnosis)·Matched via name phrase
- NCT06828822·RECRUITING·CongenItal Naevus Cohort for Longitudinal Evaluation
Conditions: Naevi · Neurodevelopmental Disorder · Congenital Nevus·Matched via name phrase
- NCT07224581·RECRUITING·Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder
Conditions: GRIN-related Neurodevelopmental Disorder·Matched via name phrase
- NCT07546942·ENROLLING BY INVITATION·Autism Spectrum Disorder (ASD) Neurodevelopmental Disorder With Issues Social Behavior, Communication Issues, GI Dysfunction. Study is Multimodal Interventions Targeting These Pathways With cSVF, Stored MSCs, FMT and Diet Modification. Role of Autoimmunity, Gut-brain Issues, & Issues Examined.
Conditions: Autism Spectrum Disorder · Autism · Autism Spectral Disorder·Matched via name phrase
- NCT06442592·RECRUITING·Characterization and Support for Neurodevelopmental Disorders Associated With Congenital Heart Defects
Conditions: Congenital Heart Defects · Neurodevelopmental Disorder·Matched via name phrase
- NCT06613126·RECRUITING·Effectiveness of Symptom Management Application on Parental Care Ability of Children With Tourette Syndrome
Conditions: Tourette Syndrome · Tic Disorder · Neurodevelopmental Disorder·Matched via name phrase
- NCT07173153·ENROLLING BY INVITATION·Gene Therapy for SLC6A1 Neurodevelopmental Disorder
Conditions: SLC6A1·Matched via name phrase
- NCT07377032·RECRUITING·TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
Conditions: GRIN-related Disorders · GRIN1 · GRIN2A · GRIN2B·Matched via name phrase
- NCT07755098·NOT YET RECRUITING·Integration of New Generation Multi-omics Analyses for the Diagnosis of Genetic Neurodevelomental Disorders
Conditions: Intellectual Disability · Neurodevelopmental Disorder (Diagnosis) · srGS · lrGS·Matched via name phrase
- NCT07431671·RECRUITING·Feeding Disorders in Children
Conditions: Neurodevelopmental Disorder (Diagnosis) · Feeding Disorder · ARFID·Matched via name phrase
- NCT06808555·NOT YET RECRUITING·Pai.ACT: AI-Driven ACT Chatbot for Mental Health Triage and Service Evaluation
Conditions: Autism Spectrum Disorder · Attention Deficit Disorder With Hyperactivity (ADHD) · Neurodevelopmental Disorder (Diagnosis) · Dyslexia·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 23 · after dedupe 23 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 23 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (23)
- ctis·2025-524576-28-00·Authorised·Intrathecal Administration of MELPIDA For Hereditary Spastic Paraplegia Type 50 (SPG50): A multicenter Phase 3, Open-Label Trial with Matched Prospective Concurrent Control Arm (CT-MEL-03)
skipped — LLM skipped (--skip-llm)
- ctis·2025-524279-22-00·Authorised, ongoing·Exploratory study on the effect of Rimonabant on hand function in patients with spinal cord injury (RIMOHANDOPEN)
skipped — LLM skipped (--skip-llm)
- ctis·2025-521877-14-00·Authorised, ongoing·Guttmann NeuroRecovery – Feasibility, safety and efficacy of intrathecal Wharton's jelly-derived mesenchymal stem cells and transcutaneous spinal cord stimulation in the rehabilitation of chronic spinal cord injuries: a pilot study
skipped — LLM skipped (--skip-llm)
- ctis·2024-518822-33-01·Authorised·Intrathecal baclofen pump versus selective dorsal rhizotomy for non-ambulatory children with cerebral palsy
skipped — LLM skipped (--skip-llm)
- ctis·2024-517745-14-00·Authorised, ongoing·A Phase 2, Randomized, Double-Blind, Four-Arm, Placebo-Controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of three doses of orally administered BMS-986368, a FAAH/MAGL Inhibitor, for the treatment of Spasticity in Participants with Multiple Sclerosis (BALANCE-MSS-1)
skipped — LLM skipped (--skip-llm)
- ctis·2024-520287-34-01·Authorised, ongoing·A phase II randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of an oral solution of 9-Δ tetrahydrocannabinol/cannabidiol (THC/CBD) in multiple sclerosis patients with chronic neuropathic pain
skipped — LLM skipped (--skip-llm)
- ctis·2024-513158-32-01·Authorised, ongoing·Exploratory, longitudinal study to define changes in muscle, tendon and neural properties after botuline neurotoxin type A (BoNT) treatment of spastic equinovarus in first-ever stroke patients: a pilot study
skipped — LLM skipped (--skip-llm)
- ctis·2024-518451-39-00·Cancelled·A Phase 1/2 Randomized, Blinded, Dose-escalation Study to Evaluate the Safety and Efficacy of Intrathecal Administration of AAV9-ABCD1 Gene Therapy (SBT101) in Adult Patients with Adrenomyeloneuropathy
skipped — LLM skipped (--skip-llm)
- ctis·2023-508457-10-00·Cancelled·Randomized, Single-blind, Placebo-controlled Clinical Trial to Evaluate the
Safety and Efficacy of Melatonin Administration in Patients With Multiple
Progressive Primary Sclerosis (MELATOMS)
skipped — LLM skipped (--skip-llm)
- ctis·2024-514303-34-00·Authorised, ongoing·A first-in-human (FIH) clinical trial to investigate the human monoclonal antibody NG004, administrated intrathecally in acute spinal cord injury (SCI) patients
skipped — LLM skipped (--skip-llm)
- ctis·2024-518147-37-00·Authorised·Upper-limb Active Function and Botulinum Toxin A
skipped — LLM skipped (--skip-llm)
- ctis·2024-518447-38-00·Authorised, ongoing·Prospective, open-label, non-randomized, single-arm, dose titration study to investigate the efficacy and safety of IncobotulinumtoxinA in children deemed to require a total body dose up to 22U/kg (maximum dose 550U) during the study period for the treatment of upper and lower limb spasticity due to cerebral palsy.
PROTOCOL CODE: INCIPIT
skipped — LLM skipped (--skip-llm)
- ctis·2024-518433-29-00·Revoked·Complexity-enhancing drugs to treat disorders of consciousness (DoC): a ketamine study
skipped — LLM skipped (--skip-llm)
- ctis·2024-517668-51-01·Authorised, ongoing·Clinical trial on the effectiveness and safety of botulinum toxin type A (incobotulinumtoxin) in doses adapted to the individual needs of patients with severe spasticity
skipped — LLM skipped (--skip-llm)
- ctis·2023-505810-12-00·Expired·Prospective, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy and safety of NT 201 in the treatment of lower limb spasticity caused by stroke or traumatic brain injury in adult subjects, followed by an open label extension with or without combined upper limb treatment
skipped — LLM skipped (--skip-llm)
- ctis·2024-514882-20-00·Authorised, ongoing·Riluzole for the treatment of spasticity in the traumatic chronic spinal cord injury condition:
Adaptive, Multicenter, placebo-controlled, randomised, double blind trial in a Rare Disorder
skipped — LLM skipped (--skip-llm)
- ctis·2024-510866-18-00·Authorised, ongoing·Comparative study of the mechanism of action of Dry Needling and Botulinum Toxin type A as a treatment for lower limb post-stroke spasticity: a proof of concept controlled trial
skipped — LLM skipped (--skip-llm)
- ctis·2023-509207-33-01·Authorised, recruiting·Phase 1b/2a clinical trial in early acute Spinal Cord Injury (SCI): A Single Blinded, Randomized, Proof-of-Concept study to determine the safety, tolerability and efficacy of TZ-161
skipped — LLM skipped (--skip-llm)
- ctis·2023-507202-14-00·Authorised, recruiting·An Integrated Phase I/II, Multicentre, Double-Blind, Randomised, Dysport and Placebo Controlled, Dose-Escalation and Dose-Finding Study to Evaluate the Safety and Efficacy of IPN10200 in the treatment of Adult Upper Limb Spasticity Followed by an Open-label Extension Period
skipped — LLM skipped (--skip-llm)
- ctis·2023-503420-19-00·Cancelled·A prospective, randomized, double-blind, placebo-controlled, two-stage, multicenter study with an open-label extension period to investigate the efficacy and safety of NT 201 in the treatment of lower limb spasticity in children and adolescents with cerebral palsy
skipped — LLM skipped (--skip-llm)
- ctis·2023-508143-51-01·Expired·Pulmonary function and sleep related disorders during cervical admission of intrathecal baclofen in spinal cord injury;
a safety study
skipped — LLM skipped (--skip-llm)
- ctis·2023-509196-16-00·Cancelled·A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport®) in Comparison with OnabotulinumtoxinA (Botox®) when Treating Adults with Upper Limb Spasticity
skipped — LLM skipped (--skip-llm)
- ctis·2023-506429-13-00·Expired·An Open-Label, Single-Arm 4-Year Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients with Progressive Multiple Sclerosis
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for PLAA-associated neurodevelopmental disorder — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("PLAA-associated neurodevelopmental disorder" OR "PLAAND" OR "neurodevelopmental disorder with progressive microcephaly, spasticity, and brain anomalies") OR ("PLAA" OR "PLAA syndrome" OR "PLAA-related")ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"PLAA-associated neurodevelopmental disorder" OR "PLAAND" OR "neurodevelopmental disorder with progressive microcephaly, spasticity, and brain anomalies"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"neurodevelopmental disorder"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (1526) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity
Ingested 2026-07-27T18:03:03.885Z
